Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer

An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib t...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/02/01, Vol.60(3), pp.441-444
Main Authors: Oyama, Baku, Morikawa, Kei, Sakaguchi, Tadashi, Tsunoda, Akihito, Kida, Hirotaka, Inoue, Takeo, Mineshita, Masamichi
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma of Lung - drug therapy
afatinib
Afatinib - adverse effects
Aged, 80 and over
Blood tests
Case Report
Diarrhea
drug-induced hypersensitivity syndrome
Epidermal growth factor
Epidermal growth factor receptors
ErbB Receptors - genetics
Erythema
Female
HHV-6
Humans
Hypersensitivity
Inflammation
Internal medicine
Lung cancer
Lung Neoplasms - drug therapy
Mutation
Pharmaceutical Preparations
Prednisolone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.4237-19